HRP20250907T1 - Inhibitori glukozilceramid sintaze - Google Patents
Inhibitori glukozilceramid sintazeInfo
- Publication number
- HRP20250907T1 HRP20250907T1 HRP20250907TT HRP20250907T HRP20250907T1 HR P20250907 T1 HRP20250907 T1 HR P20250907T1 HR P20250907T T HRP20250907T T HR P20250907TT HR P20250907 T HRP20250907 T HR P20250907T HR P20250907 T1 HRP20250907 T1 HR P20250907T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- disease
- lysosomal storage
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161454034P | 2011-03-18 | 2011-03-18 | |
| US201261590711P | 2012-01-25 | 2012-01-25 | |
| EP19207540.6A EP3673906B1 (en) | 2011-03-18 | 2012-03-16 | Glucosylceramide synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20250907T1 true HRP20250907T1 (hr) | 2025-09-26 |
Family
ID=46879977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250907TT HRP20250907T1 (hr) | 2011-03-18 | 2012-03-16 | Inhibitori glukozilceramid sintaze |
| HRP20200226TT HRP20200226T1 (hr) | 2011-03-18 | 2012-03-16 | Inhibitor glukozilceramid sintaze |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200226TT HRP20200226T1 (hr) | 2011-03-18 | 2012-03-16 | Inhibitor glukozilceramid sintaze |
Country Status (39)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012231275A1 (en) * | 2011-03-18 | 2013-10-17 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| AU2019222801B2 (en) * | 2012-09-11 | 2021-02-18 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcƩramide |
| TWI649317B (zh) * | 2013-03-15 | 2019-02-01 | å„č»å ¬åø | č£½åč”ē³åŗē„ē¶éÆčŗåęé ¶ęå¶åä¹ę¹ę³ |
| JO3713B1 (ar) * | 2013-03-15 | 2021-01-31 | Genzyme Corp | Ų£Ų“ŁŲ§Ł Ł ŁŲ (s)-ŁŁŁŁŁŁŁŁŲÆŁŁ-3-ŁŁ(2-(2-(4-ŁŁŁŲ±ŁŁŁŁŁŁ)Ų«ŁŲ§Ų²ŁŁ-4-ŁŁ)ŲØŲ±ŁŲØŲ§Ł-2-ŁŁ)ŁŲ§Ų±ŲØŲ§Ł ŁŲŖ |
| CN104418851A (zh) * | 2013-09-02 | 2015-03-18 | äøęµ·é¾ēæēē©å»čÆå¼åęéå ¬åø | å„å®ēÆč”ēē©ēå¶å¤ę¹ę³åēŗÆåę¹ę³ |
| PT3079695T (pt) * | 2013-12-11 | 2021-05-04 | Genzyme Corp | Inibidores de glicosilceramida-sintase |
| US10100012B2 (en) * | 2014-05-30 | 2018-10-16 | Sphaera Pharma Pvt. Ltd. | Compounds as anti-tubercular agents |
| ES2856898T3 (es) | 2015-02-02 | 2021-09-28 | Univ Michigan Regents | Inhibidores de glucosilceramida sintasa y mƩtodos terapƩuticos que usan los mismos |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | å„č»å ¬åø | ēØę¼ę²»ēčē½č³Ŗē č®ä¹ę¹ę³ |
| JP2018525345A (ja) | 2015-07-01 | 2018-09-06 | ćć¼ć¹ć¦ć§ć¹ćæć³ ć¦ććć¼ć·ćć£ | ē½®ęććć¾ćŖć³ååē©åć³ć°ć«ć³ć»ć¬ććć·ćć¼ć¼ę“»ę§ć®čŖæēÆć®ććć®ćć®ä½æēØ |
| CN108290894A (zh) * | 2015-07-01 | 2018-07-17 | č„æåå¤§å¦ | č¢«å代ē4-ē²åŗ-å”åÆ并[1,2-a]å§å¶-8-ē²é °čŗē±»ååē©åå ¶č°čč”ē³čč·čé ¶ę“»ę§ēēØé |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapƩuticas |
| EP3433623A2 (en) * | 2016-03-25 | 2019-01-30 | Genzyme Corporation | Biomarkers of proteopathies and uses thereof |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| EP3538095A4 (en) * | 2016-11-14 | 2020-06-17 | Berg LLC | Methods for treating parkinson's disease |
| CN110494432B (zh) | 2016-12-28 | 2022-08-12 | ē±³å°¼å„„å°å ęÆę²»ēęéå ¬åø | å¼å¹åååē©ļ¼å ¶å¶å¤ę¹ę³åå ¶åØäøĪ²-åä¹³ē³č·é ¶ę“»ę§ę¹åēøå ³ēē ēäøēę²»ēēØé |
| US11174242B2 (en) | 2016-12-29 | 2021-11-16 | Minoryx Therapeutics S.L. | Heteroaryl compounds and their use |
| CN108341822B (zh) * | 2017-01-23 | 2021-04-16 | å¹æå·åøęčÆŗåŗ·å»čÆē§ęęéå ¬åø | Fxråä½č°čååå ¶å¶å¤ę¹ę³ååŗēØ |
| EP3709986B1 (en) * | 2017-11-14 | 2023-11-01 | Merck Sharp & Dohme LLC | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| JP2021506920A (ja) | 2017-12-21 | 2021-02-22 | ćŖć½ć½ć¼ćć«ć»ć»ć©ćć„ć¼ćć£ćÆć¹ć»ć¤ć³ć³ć¼ćć¬ć¤ćććļ¼¬ļ½ļ½ļ½ļ½ļ½ļ½ļ½ļ½ ļ¼“ļ½ļ½ ļ½ļ½ļ½ļ½ ļ½ļ½ļ½ļ½ļ½ ļ¼©ļ½ļ½ļ¼ | ēµę¶ę§ć®ē½®ęć·ćÆćććć·ć«ćć©ć¾ćļ¼»ļ¼ļ¼ļ¼āļ½ļ¼½ććŖććøćć«ć«ć«ćććµććååē©ććć³ćć®ę²»ēēä½æēØ |
| US11459325B2 (en) | 2018-01-31 | 2022-10-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10519157B2 (en) * | 2018-02-09 | 2019-12-31 | X-Cutag Therapeutics, Inc. | Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof |
| KR102342901B1 (ko) * | 2018-11-22 | 2021-12-24 | (ģ£¼)ķė”ģ¤ķ ėƹģ¤ | ģģģ¢ ė° ģ“ģ ė¤ģķ ģ©ė |
| KR102342902B1 (ko) * | 2018-11-22 | 2021-12-24 | (ģ£¼)ķė”ģ¤ķ ėƹģ¤ | ģģģ¢ ė° ģ“ģ ė¤ģķ ģ©ė |
| KR102233530B1 (ko) * | 2018-11-22 | 2021-03-31 | (ģ£¼)ķė”ģ¤ķ ėƹģ¤ | ģģģ¢ ė° ģ“ģ ė¤ģķ ģ©ė |
| AU2020218496B2 (en) * | 2019-02-04 | 2024-12-19 | Genzyme Corporation | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
| CN114040762A (zh) | 2019-02-04 | 2022-02-11 | å»ŗę°å ¬åø | ä½æēØč”ē³ē„ē»é °čŗåé ¶(gcs)ēęå¶åę²»ēēŗ¤ęÆē¾ē |
| WO2020193746A1 (en) | 2019-03-28 | 2020-10-01 | INSERM (Institut National de la SantƩ et de la Recherche MƩdicale) | Methods for predicting the survival of patients suffering from melanoma |
| EP4005638A4 (en) * | 2019-07-29 | 2023-07-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2021081141A1 (en) | 2019-10-23 | 2021-04-29 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| PL4041733T3 (pl) | 2019-11-15 | 2024-09-23 | Yuhan Corporation | Pochodne majÄ ce ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierajÄ ce |
| CN114746422B (zh) * | 2019-11-15 | 2024-03-12 | ę³é©ę“č” | å ·ę1,2,3,4-åę°¢čéØåēč”ēē©ęå ¶čÆå¦äøåÆę„åēē仄åå å«å®ä»¬ēčÆē©ē»åē© |
| AU2020394602A1 (en) | 2019-11-25 | 2022-06-30 | Gt Gain Therapeutics Sa | Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase |
| BR112022010127A2 (pt) | 2019-11-25 | 2022-09-06 | Gain Therapeutics Sa | Compostos de arila e heteroarila e usos terapĆŖuticos dos mesmos em condiƧƵes associadas Ć alteraĆ§Ć£o da atividade de galatocerebrosidase |
| AU2021217816A1 (en) | 2020-02-03 | 2022-08-11 | Gt Gain Therapeutics Sa | Combination therapy for treating MPS1 |
| TW202142236A (zh) * | 2020-02-03 | 2021-11-16 | ē¾åå„č»å ¬åø | ēØę¼ę²»ēčęŗ¶é«å²ē©ēēøéēē„ē¶ēēä¹ę¹ę³ |
| WO2021214771A1 (en) | 2020-04-23 | 2021-10-28 | The Israel Institute of Biological Research (IIBR) | Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases |
| JP7725076B2 (ja) | 2020-04-28 | 2025-08-19 | ć¶ć»ćŖć¼ćøć§ć³ćć»ćŖćć»ć¶ć»ć¦ććć¼ć·ćć£ć»ćŖćć»ćć·ć¬ć³ | ć°ć«ć³ć·ć«ć»ć©ććåęé µē“ ć®ććŖćøć³é»å®³å¤åć³ććććä½æēØććę²»ēę¹ę³ |
| KR20230043024A (ko) | 2020-07-24 | 2023-03-30 | ģ ģģ ģ½ķ¬ė ģ“ģ | ė²¤źøė£Øģ¤ķķøė„¼ ķ¬ķØķė ģ ģ½ ģ”°ģ±ė¬¼ |
| EP4188381A1 (en) * | 2020-07-30 | 2023-06-07 | Genzyme Corporation | Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same |
| IL306116A (en) * | 2021-05-11 | 2023-11-01 | Yuhan Corp | New compounds with inhibitory activity against glucosylceramide synthase or an acceptable pharmaceutical salt thereof, processes for their preparation and pharmaceutical preparations containing them |
| WO2023042177A1 (en) | 2021-09-20 | 2023-03-23 | Gt Gain Therapeutics Sa | Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide |
| WO2023239892A1 (en) * | 2022-06-10 | 2023-12-14 | Arkuda Therapeutics | Compounds for modulation of cd68 and uses thereof |
| JP2025534728A (ja) * | 2022-10-24 | 2025-10-17 | ć¦ć¼ćć³ć»ć³ć¼ćć¬ć¤ć·ć§ć³ | ćøć”ćć«ļ¼ļ¼ļ¼ļ¼ļ¼ćøćććļ¼ļ¼ļ½ļ¼ć¤ć³ćć³čŖå°ä½ć®ę¹čÆćććč£½é ę¹ę³ |
| CA3268132A1 (en) * | 2022-10-24 | 2024-05-02 | Yuhan Corporation | NEW DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVE SALT AND ITS PREPARATION PROCESSES |
| CN120417900A (zh) | 2022-12-01 | 2025-08-01 | å»ŗę°å ¬åø | ęé²åøä»äøcyp3a4ēå¼ŗęäøåŗ¦ęå¶åēē»å |
| WO2024141998A1 (en) | 2022-12-30 | 2024-07-04 | Gt Gain Therapeutics Sa | Method of treating tauopathies |
| WO2025094117A1 (en) | 2023-11-02 | 2025-05-08 | Gt Gain Therapeutics Sa | Substituted indolyl compounds, compositions thereof, and therapeutic uses thereof |
| KR20250117295A (ko) * | 2024-01-26 | 2025-08-04 | ģ£¼ģķģ¬ģ ķģķ | ź³ ģ ė³ģ ģė°© ėė ģ¹ė£ģ© ģ½ģ ķģ ģ”°ģ±ė¬¼ |
| WO2025215582A1 (en) | 2024-04-11 | 2025-10-16 | Gt Gain Therapeutics Sa | Substituted pyrazolopyridine and pyrazolopyrimidine compounds and their use |
| WO2025219951A1 (en) | 2024-04-19 | 2025-10-23 | Genzyme Corporation | Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders |
| WO2025219952A1 (en) | 2024-04-19 | 2025-10-23 | Genzyme Corporation | Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders |
| WO2025262570A1 (en) | 2024-06-17 | 2025-12-26 | Genzyme Corporation | Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment |
| CN118496159B (zh) * | 2024-07-18 | 2024-09-24 | å¹æå·å»ē§å¤§å¦éå±åøå «å»é¢ | äøē§ååē©åØå¶å¤å ·ęé¢é²å/ęę²»ēčēŗ¤ē»“åä½ēØēčÆē©äøēåŗēØ |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (https=) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| AU590995B2 (en) * | 1986-10-03 | 1989-11-23 | Micro Motion, Inc. | Density insensitive coriolis mass flow rate meter |
| IE62231B1 (en) | 1987-12-24 | 1995-01-11 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| IT1228293B (it) * | 1989-02-06 | 1991-06-07 | Angeli Inst Spa | Benzoderivati di composti eterociclici contenenti azoto. |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| WO1995021820A1 (en) * | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
| JPH08198751A (ja) * | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | ć«ć«ćć”ć¼ćčŖå°ä½ |
| US5668144A (en) * | 1995-11-08 | 1997-09-16 | American Home Products Corporation | 1-azabicyclopheptane derivatives |
| IL135578A0 (en) | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| FR2791678B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
| GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| JP4445704B2 (ja) * | 2000-12-22 | 2010-04-07 | ć¢ć«ćć©ć«ć»ć½ć·ćØćććć»ć¢ććć | ćććÆćŖćøć³ć«ć«ćć”ć¼ćčŖå°ä½ććć³ļ½ļ¼ć¢ć³ćć“ćć¹ććØćć¦ć®ćććć®ä½æēØ |
| DE60216830T2 (de) * | 2001-02-06 | 2007-06-14 | Pfizer Products Inc., Groton | Pharmazeutische Zusammensetzungen zur Behandlung von Stƶrungen des ZNS oder anderen Erkrankungen |
| JP2003267977A (ja) * | 2002-03-14 | 2003-09-25 | Yamanouchi Pharmaceut Co Ltd | ćććÆćŖćøć³čŖå°ä½ |
| ES2203327B1 (es) * | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| AU2003246942B2 (en) * | 2002-07-17 | 2009-06-25 | Idorsia Pharmaceuticals Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
| JPWO2004011430A1 (ja) * | 2002-07-25 | 2005-11-24 | ć¢ć¹ćć©ć¹č£½č¬ę Ŗå¼ä¼ē¤¾ | ćććŖć¦ć ćć£ćć«é»å®³å¤ |
| SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
| WO2004052365A2 (en) * | 2002-12-06 | 2004-06-24 | North Shore-Long Island Jewish Research Institute | Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| JP2007186422A (ja) | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | ć¢ćŖć¼ć«ć¹ć«ćć£ćčŖå°ä½ |
| AU2005258274A1 (en) * | 2004-06-23 | 2006-01-05 | The Feinstein For Medical Research | Method of treating ileus by pharmacological activation of cholinergic receptors |
| US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| WO2007100430A2 (en) * | 2006-01-27 | 2007-09-07 | Yale University | Cytisine and acetylcholine analogs and methods of treating mood disorders |
| US7840109B2 (en) * | 2006-08-14 | 2010-11-23 | Adc Telecommunications, Inc. | Factory spliced cable assembly |
| BRPI0822349A2 (pt) * | 2007-11-29 | 2019-09-24 | Neuraltus Pharmaceuticals Inc | composiƧƵes e mƩtodos para tratar doenƧas lisossƓmicas |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| CA2731685A1 (en) * | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| EP2323652A2 (en) * | 2008-08-06 | 2011-05-25 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| EP2154136A1 (en) * | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
| WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| WO2010091164A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| US20100242352A1 (en) | 2009-06-09 | 2010-09-30 | Sundrop Fuels, Inc. | Systems and methods for reactor and receiver control of flux profile |
| SI3998078T1 (sl) | 2009-08-28 | 2026-02-27 | Genzyme Corporation | Encimsko nadomestno zdravljenje z naraÅ”ÄajoÄim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze |
| AU2012231275A1 (en) * | 2011-03-18 | 2013-10-17 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
-
2012
- 2012-03-16 AU AU2012231275A patent/AU2012231275A1/en not_active Abandoned
- 2012-03-16 PH PH1/2013/501944A patent/PH12013501944A1/en unknown
- 2012-03-16 UY UY33958A patent/UY33958A/es not_active Application Discontinuation
- 2012-03-16 EP EP12760259.7A patent/EP2685986B1/en active Active
- 2012-03-16 RS RS20200222A patent/RS59963B1/sr unknown
- 2012-03-16 PL PL12760259T patent/PL2685986T3/pl unknown
- 2012-03-16 ES ES19207540T patent/ES3037907T3/es active Active
- 2012-03-16 CN CN201610884699.1A patent/CN107080747B/zh active Active
- 2012-03-16 HR HRP20250907TT patent/HRP20250907T1/hr unknown
- 2012-03-16 CN CN201280024127.6A patent/CN103917094B/zh active Active
- 2012-03-16 KR KR1020137027592A patent/KR101987736B1/ko active Active
- 2012-03-16 PY PY201201212975A patent/PY1212975A/es unknown
- 2012-03-16 CR CR20190034A patent/CR20190034A/es unknown
- 2012-03-16 MX MX2013010710A patent/MX365245B/es active IP Right Grant
- 2012-03-16 LT LTEP12760259.7T patent/LT2685986T/lt unknown
- 2012-03-16 RU RU2018104472A patent/RU2018104472A/ru not_active Application Discontinuation
- 2012-03-16 LT LTEP19207540.6T patent/LT3673906T/lt unknown
- 2012-03-16 JP JP2013558205A patent/JP6117708B2/ja active Active
- 2012-03-16 ES ES12760259T patent/ES2774293T3/es active Active
- 2012-03-16 PE PE2013002075A patent/PE20140412A1/es active IP Right Grant
- 2012-03-16 BR BR122019017719-8A patent/BR122019017719B1/pt active IP Right Grant
- 2012-03-16 UA UAA201312420A patent/UA118248C2/uk unknown
- 2012-03-16 AR ARP120100873 patent/AR085425A1/es active IP Right Grant
- 2012-03-16 WO PCT/US2012/029417 patent/WO2012129084A2/en not_active Ceased
- 2012-03-16 PL PL19207540.6T patent/PL3673906T3/pl unknown
- 2012-03-16 DK DK19207540.6T patent/DK3673906T3/da active
- 2012-03-16 HU HUE19207540A patent/HUE072576T2/hu unknown
- 2012-03-16 BR BR112013023774-0A patent/BR112013023774B1/pt active IP Right Grant
- 2012-03-16 HR HRP20200226TT patent/HRP20200226T1/hr unknown
- 2012-03-16 MY MYPI2013003389A patent/MY173998A/en unknown
- 2012-03-16 EP EP19207540.6A patent/EP3673906B1/en active Active
- 2012-03-16 EP EP25169140.8A patent/EP4559918A3/en active Pending
- 2012-03-16 SI SI201231727T patent/SI2685986T1/sl unknown
- 2012-03-16 DK DK12760259.7T patent/DK2685986T3/da active
- 2012-03-16 FI FIEP19207540.6T patent/FI3673906T3/fi active
- 2012-03-16 RU RU2013146550A patent/RU2645675C2/ru active
- 2012-03-16 RS RS20250761A patent/RS67073B1/sr unknown
- 2012-03-16 HU HUE12760259A patent/HUE047888T2/hu unknown
- 2012-03-16 MX MX2018007961A patent/MX368340B/es unknown
- 2012-03-16 PT PT192075406T patent/PT3673906T/pt unknown
- 2012-03-16 TW TW101109086A patent/TWI546301B/zh active
- 2012-03-16 SI SI201232091T patent/SI3673906T1/sl unknown
- 2012-03-16 TW TW105121161A patent/TWI634119B/zh active
- 2012-03-16 PT PT127602597T patent/PT2685986T/pt unknown
- 2012-03-16 CA CA2830540A patent/CA2830540C/en active Active
- 2012-03-16 MA MA36299A patent/MA35023B1/fr unknown
-
2013
- 2013-09-17 DO DO2013000209A patent/DOP2013000209A/es unknown
- 2013-09-17 IL IL228514A patent/IL228514B/en active IP Right Grant
- 2013-09-17 NI NI201300083A patent/NI201300083A/es unknown
- 2013-09-17 CL CL2013002688A patent/CL2013002688A1/es unknown
- 2013-09-18 ZA ZA2013/07016A patent/ZA201307016B/en unknown
- 2013-09-18 GT GT201300215A patent/GT201300215A/es unknown
- 2013-09-18 MX MX2019008428A patent/MX2019008428A/es unknown
- 2013-09-18 US US14/030,725 patent/US9139580B2/en active Active
- 2013-10-17 EC ECSP13012978 patent/ECSP13012978A/es unknown
- 2013-10-17 CO CO13246820A patent/CO6801749A2/es active IP Right Grant
-
2014
- 2014-08-28 US US14/471,958 patent/US9126993B2/en active Active
-
2015
- 2015-08-25 US US14/835,402 patent/US20160207933A1/en not_active Abandoned
-
2016
- 2016-10-14 AU AU2016244305A patent/AU2016244305B2/en active Active
-
2017
- 2017-03-22 JP JP2017055577A patent/JP6420860B2/ja active Active
-
2019
- 2019-08-15 US US16/542,166 patent/US20200048266A1/en not_active Abandoned
-
2021
- 2021-04-27 US US17/242,016 patent/US20210261557A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20250907T1 (hr) | Inhibitori glukozilceramid sintaze | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| JP2014517808A5 (https=) | ||
| PE20140207A1 (es) | Composiciones y metodos para modular el fxr | |
| AR055057A1 (es) | Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria. | |
| ECSP066967A (es) | Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos | |
| NZ601220A (en) | Hepatitis c virus inhibitors | |
| HRP20220310T1 (hr) | Inhibitori glukozilceramid sintaze | |
| MX2009003410A (es) | Fosfoindoles enantiomericamente puros como inhibidores de vih. | |
| PE20141405A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| MX2011008501A (es) | Compuestos heterociclicos fusionados que contienen nitrogeno y su uso como inhibidores de la produccion de beta-amiloide. | |
| PE20090992A1 (es) | Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa | |
| ECSP088867A (es) | Derivados de pirimidina como inhibidores de fi3q | |
| TN2010000026A1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met | |
| ES2553030T3 (es) | Compuestos plaguicidas | |
| AR082985A1 (es) | INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| JP2013507434A5 (https=) | ||
| ES2222336T3 (es) | Inhibidores de girasas y sus usos. | |
| AR066169A1 (es) | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat | |
| AR079498A1 (es) | Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| UY34426A (es) | Derivados de heteroarilcarboxamida, procesos de preparaciĆ³n, composiciones y sus usos en agricultura, veterinaria y control de plagas | |
| NO20092224L (no) | Quiniklidinderivater av (hetero)arylcykloheptankarboksylsyre som muskarinreseptorantagonister | |
| WO2005095395A3 (en) | Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors |